文献速递瓣膜外科

≤60岁患者生物瓣主动脉瓣置换的长期随访

Long-term follow-up of bioprosthetic aortic valve replacement in patients aged ≤60 years.
PubMed 文献 · J Thorac Cardiovasc Surg · 2017-06-12

该研究回顾性分析1977至2013年416例≤60岁患者生物瓣主动脉瓣置换的长期耐久性,随访完整率98.5%(2423.1患者年,平均6±5.5年)。15年总体生存62.1±4.4%,无瓣膜相关死亡97.1±1.6%;15年无结构性瓣膜衰败(SVD)Kaplan-Meier分析为48.7±5.5%、竞争风险分析为61.4±4.3%。结论认为≤60岁患者生物瓣终身SVD风险可观,但首个十年耐久性一致。

要点

  • ≤60岁生物瓣AVR患者15年无SVD仅约五成(Kaplan-Meier 48.7±5.5%)。
  • 按年龄亚组分层无SVD及SVD再手术率均无显著差异。
  • 竞争风险分析下15年无SVD为61.4±4.3%,高于Kaplan-Meier估计。

核心结论

  • ≤60岁患者植入生物瓣后终身SVD风险可观,但首个十年耐久性保持一致,第二个十年需更多数据。
  • 患者信息对瓣膜选择至关重要,建议采用竞争风险方法。

研究设计与样本

  • 回顾性分析前瞻性收集数据库,1977至2013年共416例≤60岁患者生物瓣主动脉瓣置换。
  • 前瞻性随访瓣膜相关与非瓣膜相关事件,随访完整率98.5%(2423.1患者年,平均6±5.5年)。

主要发现

  • 15年总体生存62.1±4.4%,无瓣膜相关死亡97.1±1.6%。
  • 共68例SVD事件(术后11.9±28.8年),15年无SVD Kaplan-Meier分析48.7±5.5%、竞争风险分析61.4±4.3%。
  • 按<40岁、≥40且<50岁、≥50且≤60岁分层,无SVD差异无统计学意义(P = .50),SVD平均延迟亦无差异(P = .30)。
  • 57例因SVD再手术(植入后11.8±5.2年),15年无SVD再手术Kaplan-Meier分析55.4±5.6%、竞争风险分析67.1±4.2%,年龄分层后可比(P = .13)。
  • 无任何瓣膜相关并发症或死亡的15年率Kaplan-Meier分析42±5%、竞争风险分析54.4±4.1%。

临床怎么用

  • 对≤60岁拟行主动脉瓣置换患者,应告知生物瓣终身SVD风险及再手术可能。
  • 瓣膜选择咨询可结合竞争风险方法评估,强调患者信息的重要性。

局限性

  • 为单中心回顾性数据库分析,跨1977至2013年,时代与瓣膜类型可能影响耐久性。
  • 平均随访仅6±5.5年,第二个十年数据有限,需更多资料。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To address the long-term durability of bioprostheses used for aortic valve replacement (AVR) in adult patients aged ≤60 years at the time of surgery. METHODS: Through a retrospective review of a prospectively collected database, we identified 416 bioprosthetic AVRs performed between 1977 and 2013. A prospective follow-up of valve-related and non-valve-related events was performed. RESULTS: Follow-up was 98.5% complete (2423.1 patient-years; average, 6 ± 5.5 years). At 15 years, overall survival was 62.1 ± 4.4%; freedom from valve-related death was 97.1 ± 1.6%. There were 68 SVD events (11.9 ± 28.8 years after surgery). Freedom from SVD at 15 years was 48.7 ± 5.5% for Kaplan-Meier analysis and 61.4 ± 4.3% for competing-risks analysis. After stratification into age subgroups (<40 years, ≥40 and <50 years, and ≥50 and ≤60 years), we observed no significant difference in freedom from SVD (P = .50). The average delay to SVD was not statistically different among subgroups (P = .30). There were 57 reoperations for SVD (11.8 ± 5.2 years after implantation). The 15 year freedom from reoperation for SVD was 55.4 ± 5.6% by Kaplan-Meier analysis and 67.1 ± 4.2% by competing-risks analysis. After stratification by age, freedom from reoperation for SVD was comparable (P = .13). Freedom from any valve-related complication or death was 42 ± 5% by Kaplan-Meier analysis and 54.4 ± 4.1% by competing-risks analysis. CONCLUSIONS: The lifetime risk of SVD is considerable in patients aged ≤60 years at the time of bioprosthesis implantation. Nonetheless, durability remains consistent during the first decade; additional data are required for the second decade. Patients' information is pivotal for valve choice (competing-risks method).

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Anselmi A, Flecher E, Chabanne C, et al. Long-term follow-up of bioprosthetic aortic valve replacement in patients aged ≤60 years. J Thorac Cardiovasc Surg. 2017. PMID: 28688707. doi:10.1016/j.jtcvs.2017.05.103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。